\-\ Texto\\:\\ \ \(0\)\
\-\ pe\\:\\ unremarkable\ \(0\)\
\-\ lab\\:\\ \\ esr\\-25\\,\\ crp\\-1\\.40\ \(0\)\
\-\ patient\\ was\\ started\\ on\\ prednisone\\ 50\\ mg\\ daily\\ by\\ her\\ ophthalmologist\\ in\\ consultation\\ with\\ rheumatology\\.\ \(0\)\
\-\ there\\ is\\ diffuse\\ abnormal\\ fdg\\ uptake\\ involving\\ the\\ aortic\\ arch\\ and\\ its\\ major\\ branches\\.\\ additionally\\,\\ there\\ is\\ low\\ level\\ fdg\\ uptake\\ involving\\ the\\ descending\\ thoracic\\ aorta\\,\\ as\\ well\\ as\\ the\\ abdominal\\ aorta\\.\\ the\\ diffuse\\ abnormal\\ uptake\\ continues\\ to\\ involve\\ the\\ external\\ iliac\\ artery\\ and\\ into\\ the\\ superficial\\ femoral\\ arteries\\ bilaterally\\.\ \(0\)\
\-\ giant\\ cell\\ arteritis\ \(7\)\
\-\ giant\\ cell\\ arteritis\\ \\ \\ \\ \\ \ \(0\)\
\-\ takayasu\\ arteritis\\-imaging\\ would\\ be\\ essentially\\ the\\ same\\ as\\ giant\\ cell\\ arteritis\\,\\ however\\ can\\ be\\ generally\\ distinguished\\ based\\ upon\\ demographics\\.\\ \\ giant\\ cell\\ arteritis\\ occurs\\ almost\\ exclusively\\ in\\ older\\ patients\\,\\ while\\ takaysu\\ arteritis\\ occurs\\ in\\ patients\\ aged\\ 20\\-40\\.\\ \\ \ \(0\)\
\-\ atherosclerosis\\-pet\\ would\\ show\\ mild\\ heterogeneous\\ enhancement\\ with\\ skipped\\ areas\\,\\ while\\ more\\ severe\\ atherosclerosis\\ could\\ demonstrate\\ ulcerated\\ plaques\\.\ \(0\)\
\-\ vascular\\ thrombosis\\-would\\ show\\ increased\\ fdg\\ uptake\\ in\\ the\\ lumen\\ rather\\ than\\ the\\ vessel\\ wall\\.\ \(0\)\
\-\ 81\\ year\\ old\\ female\\ history\\ of\\ vasculitis\\ s\\/p\\ long\\-term\\ corticosteroid\\ treatment\\ and\\ colon\\ cancer\\ s\\/p\\ resection\\ presents\\ with\\ increasing\\ esr\\/crp\\ on\\ pre\\-operative\\ evaluation\\ for\\ cataract\\ surgery\\.\ \(0\)\
\-\ this\\ patient\\ had\\ a\\ previous\\ biopsy\\ proven\\ diagnosis\\ of\\ giant\\ cell\\ arteritis\\,\\ but\\ had\\ concluded\\ her\\ extended\\ course\\ of\\ corticosteroids\\.\\ \\ \ \(0\)\
\-\ determining\\ disease\\ recurrence\\ can\\ be\\ difficult\\,\\ especially\\ in\\ a\\ patient\\ such\\ as\\ this\\ who\\ had\\ no\\ recurrence\\ in\\ symptoms\\ and\\ whose\\ only\\ sign\\ was\\ increasing\\ esr\\/crp\\,\\ which\\ are\\ imperfect\\ markers\\ for\\ disease\\ activity\\.\\ \\ imaging\\ can\\ be\\ helpful\\ in\\ assessing\\ for\\ recurrence\\,\\ though\\ imaging\\ findings\\ do\\ not\\ necessarily\\ correlate\\ with\\ disease\\ activity\\,\\ as\\ low\\ level\\ changes\\ can\\ persist\\ on\\ imaging\\ despite\\ clinically\\ inactive\\ disease\\.\\ \\ \ \(0\)\
\-\ in\\ this\\ case\\ there\\ was\\ clearly\\ active\\ disease\\ with\\ diffuse\\ increased\\ vascular\\ uptake\\ in\\ large\\ arteries\\,\\ from\\ the\\ carotids\\ and\\ vertebral\\ arteries\\ through\\ the\\ aorta\\ and\\ into\\ the\\ external\\ iliacs\\ and\\ superficial\\ femorals\\.\\ \\ \ \(0\)\
\-\ such\\ diffuse\\ activity\\ was\\ previously\\ thought\\ to\\ be\\ rare\\,\\ but\\ with\\ increased\\ use\\ of\\ imaging\\ such\\ as\\ mri\\ and\\ pet\\ in\\ recent\\ years\\,\\ it\\ is\\ now\\ evident\\ that\\ giant\\ cell\\ arteritis\\ is\\ a\\ systemic\\ disease\\.\\ \\ in\\ a\\ prospective\\ study\\ of\\ 35\\ patients\\ with\\ biopsy\\ proven\\ giant\\ cell\\ arteritis\\ by\\ blockmans\\ et\\ al\\,\\ increased\\ vascular\\ fdg\\ uptake\\ was\\ noted\\ on\\ pet\\ in\\ 29\\ patients\\ \\(83\\%\\)\\,\\ with\\ subclavian\\ arteries\\ involved\\ in\\ 74\\%\\,\\ the\\ aorta\\ in\\ greater\\ than\\ 50\\%\\ and\\ the\\ femoral\\ arteries\\ in\\ 37\\%\\.\ \(0\)\
\-\ in\\ this\\ patient\\ with\\ recent\\ history\\ of\\ colon\\ cancer\\,\\ pet\\ also\\ served\\ as\\ surveillance\\ for\\ disease\\ recurrence\\.\\ \\ her\\ visceral\\ organs\\ did\\ not\\ show\\ any\\ increased\\ fdg\\ uptake\\ to\\ suggest\\ recurrence\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ arteritis\\:\\ 0\\.4310127076538492\ \(0\)\
\-\ giant\\:\\ 0\\.25857337103995204\ \(0\)\
\-\ fdg\\:\\ 0\\.22425308133309746\ \(0\)\
\-\ uptake\\:\\ 0\\.22290166414263962\ \(0\)\
\-\ recurrence\\:\\ 0\\.1709543112860411\ \(0\)\
\-\ cell\\:\\ 0\\.16582542069356332\ \(0\)\
\-\ in\\:\\ 0\\.16482981229263316\ \(0\)\
\-\ arteries\\:\\ 0\\.16433637067955714\ \(0\)\
\-\ pet\\:\\ 0\\.15341258131697003\ \(0\)\
\-\ aorta\\:\\ 0\\.13456122173725188\ \(0\)\
\-\ disease\\:\\ 0\\.1216818434126677\ \(0\)\
\-\ as\\:\\ 0\\.11645557920443399\ \(0\)\
\-\ the\\:\\ 0\\.11568361938221008\ \(0\)\
\-\ increased\\:\\ 0\\.11196713328550834\ \(0\)\
\-\ imaging\\:\\ 0\\.10881599862596542\ \(0\)\
\-\ diffuse\\:\\ 0\\.1038808076208187\ \(0\)\
\-\ patients\\:\\ 0\\.09318516973592314\ \(0\)\
\-\ atherosclerosis\\:\\ 0\\.09174959105002195\ \(0\)\
\-\ activity\\:\\ 0\\.09121106114397189\ \(0\)\
\-\ would\\:\\ 0\\.08794354527389643\ \(0\)\
\-\ can\\:\\ 0\\.08692599283180154\ \(0\)\
\-\ be\\:\\ 0\\.0839951623713366\ \(0\)\
\-\ proven\\:\\ 0\\.08356165897324706\ \(0\)\
\-\ vascular\\:\\ 0\\.08201791540287447\ \(0\)\
\-\ superficial\\:\\ 0\\.08002444373264009\ \(0\)\
\-\ such\\:\\ 0\\.07991416433381432\ \(0\)\
\-\ show\\:\\ 0\\.07886711865936259\ \(0\)\
\-\ her\\:\\ 0\\.07761486430574202\ \(0\)\
\-\ and\\:\\ 0\\.07701480996684167\ \(0\)\
\-\ with\\:\\ 0\\.07298018926755913\ \(0\)\
\-\ was\\:\\ 0\\.07216177113153761\ \(0\)\
\-\ external\\:\\ 0\\.06695794710485128\ \(0\)\
\-\ takaysu\\:\\ 0\\.0662261712214967\ \(0\)\
\-\ imperfect\\:\\ 0\\.0662261712214967\ \(0\)\
\-\ femorals\\:\\ 0\\.0662261712214967\ \(0\)\
\-\ blockmans\\:\\ 0\\.0662261712214967\ \(0\)\
\-\ occurs\\:\\ 0\\.06530110498507993\ \(0\)\
\-\ increasing\\:\\ 0\\.06523010595937478\ \(0\)\
\-\ skipped\\:\\ 0\\.06328264216147016\ \(0\)\
\-\ colon\\:\\ 0\\.06306294936270596\ \(0\)\
\-\ had\\:\\ 0\\.06189835213564029\ \(0\)\
\-\ femoral\\:\\ 0\\.06155761406280292\ \(0\)\
\-\ iliacs\\:\\ 0\\.0611941750569602\ \(0\)\
\-\ served\\:\\ 0\\.0611941750569602\ \(0\)\
\-\ biopsy\\:\\ 0\\.058056116606075216\ \(0\)\
\-\ involving\\:\\ 0\\.058012968663994455\ \(0\)\
\-\ 50\\:\\ 0\\.05784164783469272\ \(0\)\
\-\ this\\:\\ 0\\.05691909252469531\ \(0\)\
\-\ recent\\:\\ 0\\.05607957656296944\ \(0\)\
\-\ inactive\\:\\ 0\\.05530711693690712\ \(0\)\
\-\ cancer\\:\\ 0\\.05516611363030178\ \(0\)\
\-\ cataract\\:\\ 0\\.054542237953693944\ \(0\)\
\-\ patient\\:\\ 0\\.05387646437577273\ \(0\)\
\-\ while\\:\\ 0\\.05352698874497378\ \(0\)\
\-\ ophthalmologist\\:\\ 0\\.05263756891724869\ \(0\)\
\-\ rheumatology\\:\\ 0\\.05209957202121016\ \(0\)\
\-\ ulcerated\\:\\ 0\\.05209957202121016\ \(0\)\
\-\ demographics\\:\\ 0\\.051598708893667404\ \(0\)\
\-\ carotids\\:\\ 0\\.051598708893667404\ \(0\)\
\-\ takayasu\\:\\ 0\\.05113018272788719\ \(0\)\
\-\ concluded\\:\\ 0\\.05113018272788719\ \(0\)\
\-\ whose\\:\\ 0\\.05113018272788719\ \(0\)\
\-\ necessarily\\:\\ 0\\.05113018272788719\ \(0\)\
\-\ for\\:\\ 0\\.05020615823503185\ \(0\)\
\-\ level\\:\\ 0\\.05003001090597119\ \(0\)\
\-\ on\\:\\ 0\\.05002806173289701\ \(0\)\
\-\ abnormal\\:\\ 0\\.04975907515617344\ \(0\)\
\-\ there\\:\\ 0\\.04943264695160128\ \(0\)\
\-\ exclusively\\:\\ 0\\.04915604296118362\ \(0\)\
\-\ assessing\\:\\ 0\\.04915604296118362\ \(0\)\
\-\ distinguished\\:\\ 0\\.048818324585037515\ \(0\)\
\-\ of\\:\\ 0\\.048624406440444475\ \(0\)\
\-\ visceral\\:\\ 0\\.04818665366786065\ \(0\)\
\-\ determining\\:\\ 0\\.04789030085042769\ \(0\)\
\-\ markers\\:\\ 0\\.04789030085042769\ \(0\)\
\-\ prospective\\:\\ 0\\.04789030085042769\ \(0\)\
\-\ low\\:\\ 0\\.047524405972002\ \(0\)\
\-\ persist\\:\\ 0\\.04706757585667366\ \(0\)\
\-\ than\\:\\ 0\\.04695012262348457\ \(0\)\
\-\ corticosteroid\\:\\ 0\\.04681282565116003\ \(0\)\
\-\ correlate\\:\\ 0\\.04565807388163952\ \(0\)\
\-\ is\\:\\ 0\\.04536339717323969\ \(0\)\
\-\ aged\\:\\ 0\\.04524312460783411\ \(0\)\
\-\ surveillance\\:\\ 0\\.04524312460783411\ \(0\)\
\-\ corticosteroids\\:\\ 0\\.04485061626661949\ \(0\)\
\-\ into\\:\\ 0\\.044027392309172096\ \(0\)\
\-\ 81\\:\\ 0\\.04378632842050101\ \(0\)\
\-\ prednisone\\:\\ 0\\.04362318366910436\ \(0\)\
\-\ extended\\:\\ 0\\.04271454482161297\ \(0\)\
\-\ organs\\:\\ 0\\.04271454482161297\ \(0\)\
\-\ 83\\:\\ 0\\.04203557969213716\ \(0\)\
\-\ essentially\\:\\ 0\\.041907087206592954\ \(0\)\
\-\ consultation\\:\\ 0\\.04178082948662353\ \(0\)\
\-\ plaques\\:\\ 0\\.04178082948662353\ \(0\)\
\-\ 74\\:\\ 0\\.04118051773662058\ \(0\)\
\-\ branches\\:\\ 0\\.041066190398814185\ \(0\)\
\-\ but\\:\\ 0\\.04095620645476973\ \(0\)\
\-\ continues\\:\\ 0\\.03953756683912697\ \(0\)\
\-\ daily\\:\\ 0\\.03926699008295365\ \(0\)\
\-\ helpful\\:\\ 0\\.03926699008295365\ \(0\)\
\-\ clearly\\:\\ 0\\.03900613677837326\ \(0\)\
\-\ subclavian\\:\\ 0\\.03875433225596451\ \(0\)\
\-\ older\\:\\ 0\\.03843162864403807\ \(0\)\
\-\ vasculitis\\:\\ 0\\.03843162864403807\ \(0\)\
\-\ iliac\\:\\ 0\\.038122661338787646\ \(0\)\
\-\ lab\\:\\ 0\\.037403297463364495\ \(0\)\
\-\ descending\\:\\ 0\\.037403297463364495\ \(0\)\
\-\ almost\\:\\ 0\\.03720068982287963\ \(0\)\
\-\ lumen\\:\\ 0\\.036875091042056454\ \(0\)\
\-\ systemic\\:\\ 0\\.036748833322087025\ \(0\)\
\-\ rather\\:\\ 0\\.036686518468122604\ \(0\)\
\-\ involve\\:\\ 0\\.03644247411311483\ \(0\)\
\-\ vessel\\:\\ 0\\.036323461022927106\ \(0\)\
\-\ major\\:\\ 0\\.03620636758262493\ \(0\)\
\-\ mg\\:\\ 0\\.03614852157208408\ \(0\)\
\-\ 29\\:\\ 0\\.036091132847040665\ \(0\)\
\-\ despite\\:\\ 0\\.036034194234277686\ \(0\)\
\-\ though\\:\\ 0\\.035977698728049595\ \(0\)\
\-\ thought\\:\\ 0\\.03575601323086945\ \(0\)\
\-\ evident\\:\\ 0\\.035594081552566506\ \(0\)\
\-\ 37\\:\\ 0\\.03528066730327973\ \(0\)\
\-\ by\\:\\ 0\\.03517153822768083\ \(0\)\
\-\ arch\\:\\ 0\\.03512889238335728\ \(0\)\
\-\ generally\\:\\ 0\\.0350789977820586\ \(0\)\
\-\ started\\:\\ 0\\.03488277946132814\ \(0\)\
\-\ clinically\\:\\ 0\\.034414253295547925\ \(0\)\
\-\ difficult\\:\\ 0\\.034369021772824526\ \(0\)\
\-\ do\\:\\ 0\\.03432407032324453\ \(0\)\
\-\ pe\\:\\ 0\\.034234993918417146\ \(0\)\
\-\ additionally\\:\\ 0\\.034103395706232054\ \(0\)\
\-\ suggest\\:\\ 0\\.03364030543431297\ \(0\)\
\-\ previously\\:\\ 0\\.03324350525974111\ \(0\)\
\-\ 35\\:\\ 0\\.03320499251205754\ \(0\)\
\-\ involved\\:\\ 0\\.03320499251205754\ \(0\)\
\-\ al\\:\\ 0\\.03290403186463024\ \(0\)\
\-\ same\\:\\ 0\\.0327581046213503\ \(0\)\
\-\ especially\\:\\ 0\\.0327581046213503\ \(0\)\
\-\ not\\:\\ 0\\.03269663290054212\ \(0\)\
\-\ upon\\:\\ 0\\.03257972621453943\ \(0\)\
\-\ et\\:\\ 0\\.032440113528844364\ \(0\)\
\-\ aortic\\:\\ 0\\.032004069009701035\ \(0\)\
\-\ use\\:\\ 0\\.031685612868931755\ \(0\)\
\-\ history\\:\\ 0\\.031643260673921\ \(0\)\
\-\ vertebral\\:\\ 0\\.03162356432101135\ \(0\)\
\-\ previous\\:\\ 0\\.03129146485839061\ \(0\)\
\-\ rare\\:\\ 0\\.03126201396237148\ \(0\)\
\-\ to\\:\\ 0\\.031058459478095622\ \(0\)\
\-\ thoracic\\:\\ 0\\.030945702563513092\ \(0\)\
\-\ active\\:\\ 0\\.03075136036009824\ \(0\)\
\-\ its\\:\\ 0\\.03064259973544753\ \(0\)\
\-\ course\\:\\ 0\\.03058882440872814\ \(0\)\
\-\ greater\\:\\ 0\\.030508901004282284\ \(0\)\
\-\ could\\:\\ 0\\.030121972706318827\ \(0\)\
\-\ based\\:\\ 0\\.02999744759636058\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.02997279685650434\ \(0\)\
\-\ did\\:\\ 0\\.029707023432513423\ \(0\)\
\-\ sign\\:\\ 0\\.028669745201271413\ \(0\)\
\-\ now\\:\\ 0\\.028427060678792346\ \(0\)\
\-\ areas\\:\\ 0\\.02811560762247763\ \(0\)\
\-\ unremarkable\\:\\ 0\\.027762316192281675\ \(0\)\
\-\ bilaterally\\:\\ 0\\.027618556328003464\ \(0\)\
\-\ study\\:\\ 0\\.027618556328003464\ \(0\)\
\-\ any\\:\\ 0\\.02676349437248689\ \(0\)\
\-\ resection\\:\\ 0\\.02654537731615345\ \(0\)\
\-\ severe\\:\\ 0\\.026215337032645173\ \(0\)\
\-\ only\\:\\ 0\\.025871621435247343\ \(0\)\
\-\ artery\\:\\ 0\\.02571936419556174\ \(0\)\
\-\ years\\:\\ 0\\.02538475953849075\ \(0\)\
\-\ evaluation\\:\\ 0\\.02525511973790467\ \(0\)\
\-\ wall\\:\\ 0\\.02519115777425369\ \(0\)\
\-\ changes\\:\\ 0\\.025027446991441812\ \(0\)\
\-\ through\\:\\ 0\\.024651341648557142\ \(0\)\
\-\ however\\:\\ 0\\.02451082817979644\ \(0\)\
\-\ enhancement\\:\\ 0\\.02383579876674631\ \(0\)\
\-\ mild\\:\\ 0\\.023475061311742287\ \(0\)\
\-\ who\\:\\ 0\\.023424960105903024\ \(0\)\
\-\ more\\:\\ 0\\.022739400248956924\ \(0\)\
\-\ symptoms\\:\\ 0\\.022658084248543757\ \(0\)\
\-\ abdominal\\:\\ 0\\.022649105105887177\ \(0\)\
\-\ surgery\\:\\ 0\\.022264630211253765\ \(0\)\
\-\ noted\\:\\ 0\\.021956372166510217\ \(0\)\
\-\ demonstrate\\:\\ 0\\.02152874546616108\ \(0\)\
\-\ diagnosis\\:\\ 0\\.02146748235227997\ \(0\)\
\-\ mri\\:\\ 0\\.02125704338858436\ \(0\)\
\-\ it\\:\\ 0\\.021198021633298474\ \(0\)\
\-\ case\\:\\ 0\\.020804739879638406\ \(0\)\
\-\ large\\:\\ 0\\.02074926961234046\ \(0\)\
\-\ findings\\:\\ 0\\.020438287939764203\ \(0\)\
\-\ well\\:\\ 0\\.020051703130064963\ \(0\)\
\-\ female\\:\\ 0\\.01998300928844909\ \(0\)\
\-\ presents\\:\\ 0\\.01992111943439184\ \(0\)\
\-\ treatment\\:\\ 0\\.019726544680775566\ \(0\)\
\-\ also\\:\\ 0\\.019478832015259934\ \(0\)\
\-\ which\\:\\ 0\\.01883026867567989\ \(0\)\
\-\ that\\:\\ 0\\.017971083432991218\ \(0\)\
\-\ from\\:\\ 0\\.016446933710608045\ \(0\)\
\-\ are\\:\\ 0\\.015713820588803145\ \(0\)\
\-\ no\\:\\ 0\\.013466582631725062\ \(0\)\
\-\ year\\:\\ 0\\.012762241238623117\ \(0\)\
\-\ old\\:\\ 0\\.012256169348516602\ \(0\)\
